

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023192 A1

(51) International Patent Classification:

A61K 31/48 (2006.01) A61P 25/28 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2022/040653

(22) International Filing Date:

17 August 2022 (17.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/234,773 19 August 2021 (19.08.2021) US

(71) Applicant: **MIND MEDICINE, INC.** [US/US]; One World Trade Center, Suite 8500, New York, New York 10007 (US).

(72) Inventors: **MACK, Peter**; 201 Old Larkspur Way, Chapel Hill, North Carolina 27516 (US). **MELTON, Dustin**; 201 Emerson Drive, Melbane, North Carolina 27302 (US). **DOTY, Bethany Amber**; 276 Heathwood Drive, Clayton, North Carolina 27527 (US). **SCHROEDER, Jon**; 617 South Brearly Street, Madison, Wisconsin 53703 (US). **COGHILL, James**; 42 Westbourne Terrace, READING Berkshire RG30 2RP (GB). **LEVY, Daniel Emil**; 37 Lakewood Circle, San Mateo, CA 84402 (US).

(74) Agent: **KOHN, Kenneth I.**; 30500 Northwestern Highway, Suite 410, Farmington Hills, Michigan 48334 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):


ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(54) Title: IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS

FIGURE 1



$C_{24}H_{31}N_3O_7$
Mol. Wt.: 473.52

D-LSD D-Tartrate

(57) Abstract: A solid oral immediate release formulation of LSD, including LSD contained within a dosage form of a capsule, tablet, or orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD as a free base or in a salt form by granulation, including moisture-activated dry granulation or dry blending. A method of treating an individual, by administering a solid oral immediate release formulation of LSD and treating the individual.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*